with sales of around £114 million in the last quarter. GSK's drug was also last year approved in a self-injectable subcutaneous formulation. But Anifrolumab works in a different way and is not an ...
AstraZeneca has completed the resurrection of its anifrolumab drug for systemic lupus ... Benlysta has grown slowly towards its predicted blockbuster sales levels, just about breaching the $1 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback